United States Health

Lexeo Therapeutics (NASDAQ:LXEO) agreed to acquire Mantle Therapeutics for up to $21.3 million to expand its Friedreich ataxia drug development portfolio.

MediWound (NASDAQ:MDWD) received an additional $3.3 million in non-dilutive funding to support development of a room-temperature-stable NexoBrid formulation for battlefield burn care.

Viking Therapeutics (NASDAQ:VKTX) announced positive topline results from a 33-week clinical study evaluating VK2735, its investigational GLP-1/GIP receptor agonist being developed for obesity treatment.

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved an update to the U.S. prescribing information for WINREVAIR™ (sotatercept-csrk).

Summit Therapeutics (NASDAQ:SMMT) announced that data from the Phase III HARMONi-GI1 trial evaluating ivonescimab, a potential first-in-class investigational bispecific antibody, will be presented at the Presidential Symposium II during the European Society for Medical Oncology (ESMO) 2026 Congress.

Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities.

AbbVie (NYSE:ABBV) announced that the European Commission has approved RINVOQ® (upadacitinib) 15 mg tablets and 1 mg/mL oral solution for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA).

ADARx Pharmaceuticals announced plans to pursue a U.S. initial public offering that could value the rare disease-focused biotechnology company at up to approximately $1.74 billion.

Tiziana Life Sciences (NASDAQ:TLSA) announced that the final patient has completed the final visit in its Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

NewAmsterdam Pharma (NASDAQ:NAMS) and partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo® (10 mg obicetrapib monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe).

Anixa Biosciences (NASDAQ:ANIX) announced that it received its first Australian composition-of-matter patent for its breast cancer vaccine technology.

Johnson & Johnson (NYSE:JNJ) announced positive topline results from a pivotal Phase 3 trial evaluating CAPLYTA® (lumateperone) 42 mg once daily for the treatment of acute manic episodes in adults with bipolar I disorder.